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BACKGROUND: The aim of the present study was to evaluate the effect of GnRH analogues on the in-vitro eutopic
endometrial cell apoptosis and release of interleukin-1b (IL-1b) and vascular endothelial growth factor (VEGF).
METHODS: Biopsy specimens of eutopic endometrium obtained from 16 women with untreated endometriosis and
14 controls were studied. Apoptosis, IL-1b and VEGF release were evaluated in epithelial endometrial cell cultures
after incubation with leuprolide acetate (LA) as GnRH agonist, antide as GnRH antagonist, and a combination of
both. The percentage of apoptotic cells was evaluated by the acridine orange±ethidium bromide technique, and
IL-1b and VEGF concentrations were assessed by using commercial enzyme-linked immunosorbent assay (ELISA)
kits. RESULTS: We found that LA (100 ng/ml) enhanced apoptosis in endometrial cell cultures from endometriosis
patients and controls and this effect was reversed by antide at 10±7 mol/l. IL-1b and VEGF release was down-regu-
lated by LA in cultures from controls and endometriosis patients. The addition of antide 10±7 mol/l reversed this
inhibition. Endometrial cultures treated with antide at 10±7 mol/l did not show any signi®cant effects compared with
basal conditions. CONCLUSIONS: GnRH agonists appear to have a direct effect in endometrial cells cultures, by
enhancing the percentage of apoptotic cells and decreasing the release of pro-mitogenic cytokines such as IL-1b and
VEGF.
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Introduction
Endometriosis is one of the most common benign disorders of
the female pelvis during the reproductive years. It is now
generally accepted that the pathogenesis of peritoneal endome-
triosis involves the implantation of exfoliated endometrium.
Essential for its survival is the generation and maintenance of
an extensive blood supply, both within and surrounding the
ectopic tissue (McLaren, 2000). Accordingly, a number of
studies have shown that for its survival, established ectopic
tissue is dependent upon the peritoneal environment that
supports angiogenesis (McLaren, 2000; Smith, 2001).
The vascular endothelial growth factor (VEGF) family of
angiogenic molecules is involved in both physiological
angiogenesis and a number of pathological conditions that
are characterized by excessive angiogenesis (Liu et al., 2000;
Bachelder et al., 2001; Harris et al., 2002). Increasing evidence
suggests that VEGF may also be involved in the aetiology and
maintenance of endometriosis (Donnez et al., 1998; McLaren,
2000; Smith, 2001).
VEGF is a highly speci®c mitogen for vascular endothelial
cells (Neufeld et al., 1999). Several reports have demonstrated
that VEGF not only induces angiogenesis, but also works as a
survival factor for tumour and endothelial cells, protecting
them from apoptosis (Liu et al., 2000; Harmey and Bouchier-
Hayes, 2002). We recently reported on the increased survival
capability of the eutopic endometrium from patients with
endometriosis, possibly regulated by an elevated expression of
Bcl-2, as well as on the impact of short-term oral contracep-
tives in reversing this effect (Meresman et al., 2000, 2002).
An immunological basis, mediated through various factors,
has long been considered to be important in the pathogenesis of
endometriosis (Sidell et al., 2002). Interleukin-1b (IL-1b) is a
pleiotrophic cytokine involved in the in¯ammatory immune
response (Dinarello, 1997) and is known to act as a growth
factor. In addition to its mitogenic effects, IL-1b induces the
protection of different cells from apoptotic death (Markstrom
et al., 2002; Simonart et al., 2002).
Both, IL-1b and VEGF are produced by endometrial cells
and are critical factors involved in the pathogenesis of
endometriosis (Donnez et al., 1998; Lebovic et al., 2000).
In¯ammatory cytokines, such as IL-1b and IL-6, were found to
be elevated in the peritoneal ¯uid of women with endometriosis
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(Ho et al., 1997). In endometriotic cells, as in other tissues, the
expression of VEGF was found to be potentiated by a variety of
cytokines, especially IL-1b (Lebovic et al., 2000; Jung et al.,
2001; Dias et al., 2002).
Among the most widely used hormonal treatments for
endometriosis are the GnRH analogues (Rice et al., 2002).
Leuprolide acetate (LA) is a GnRH agonist commonly
prescribed for the treatment of endometriosis that acts primarily
on the anterior pituitary, inducing initially an undesirable
transient rise in gonadotrophin release. With continued admin-
istration, LA causes pituitary desensitization, leading to a
complete suppression of gonadal function (Plosker et al., 1994).
In addition, there is growing evidence supporting a direct action
of GnRH agonists on endometrial growth, since both GnRH and
GnRH receptors have been isolated from eutopic and ectopic
endometrium (Borroni et al., 2000). It was suggested that
GnRH may act as a direct regulator of this growth.
We recently showed that GnRH agonists have a bene®cial
effect on endometriosis, by diminishing cell proliferation and
enhancing apoptosis in eutopic endometrium (Meresman et al.,
2003). Nevertheless, the effect of GnRH agonists on the release
of regulatory cytokines and angiogenic factors by the eutopic
endometrium from patients with endometriosis, as well as the
direct effect of GnRH antagonists on the same tissue, is as yet
unknown.
Based on these data, the objectives of this work are (i) to
study and compare the direct effect of a GnRH agonist and a
GnRH antagonist on apoptosis in epithelial cells from eutopic
endometrium obtained from endometriosis and control pa-
tients; and (ii) to evaluate the effect of a GnRH agonist and
antagonist on the release of IL-1b and VEGF by the same
endometrial cells in culture.
Materials and methods
Patients
A total of 30 infertile patients undergoing a diagnostic laparoscopy
participated in the study: 16 patients were found to have endometriosis
(stages I and II), while 14 patients without the disease served as
controls. Staging of endometriosis was performed according to the
American Society for Reproductive Medicine (1997). Control subjects
were infertile women without endometriosis, with either tubal factor
infertility or unexplained infertility, undergoing a diagnostic
laparoscopy. All patients in the study had regular menstrual cycles
and had not received any hormonal therapy during the previous
6 months. Biopsy specimens of eutopic endometrium were obtained
from all subjects during the proliferative phase, as previously
described (Meresman et al., 2000).
This study was approved by the Ethics and Research Committee of
the Biology and Experimental Medicine Institute, and all subjects
included in the study signed informed consent.
Epithelial endometrial cell culture
The tissue was immediately placed into culture medium and processed
within 60 min of collection. Epithelial cells were enzymatically
separated, isolated by successive centrifugation, and primary cultures
established for in-vitro studies on implantation using a modi®cation of
the method described by Bongso et al. (1988).
Brie¯y, the explant was minced, washed and placed in basic
medium (MEM D-Val, Gibco, Paisley, UK) containing 100 IU/ml
penicillin, 100 mg/ml streptomycin and 25 mg/ml amphotericin B
(Gibco) with 1 mg/ml collagenase (Gibco, type I). After a 2 h
incubation at 37°C in an atmosphere of 5% CO2, the resulting
suspension was centrifuged at 100 g for 5 min. The pellet containing
glands was resuspended in nutrient medium and spun again at 100 g
for 5 min. The ®nal pellet mainly contained epithelial cells. After a 1 h
incubation, the medium containing enriched epithelial cells was
removed and plated in fresh medium. The cells were cultured in
quadruplicate for each patient, with 10% fetal bovine serum (FBS;
Gibco) before the experiments.
Immunocytochemical evaluation for cytokeratin was done as
described in our previous study, and the cells were identi®ed as
epithelial based on their intense labelling (Meresman et al., 2003).
Apoptosis assay
Cultures of epithelial cells were plated in 4-well culture dishes (Nalge
Nunc International, NY) and left undisturbed at 37°C for 2 days. Prior
to the addition of the different agents, the medium was changed to a
low serum medium (MEM D-Val supplemented with 2.5% FBS).
Cultures were treated with LA (Lupron; Abbot, Buenos Aires,
Argentina) 100 ng/ml, as GnRH agonist, antide (ANT) (Sigma, St
Louis, MO) at a concentration of 10±7 mol/l, as GnRH antagonist, or a
combination of ANT and LA, adding LA 100 ng/ml 3 h after the
supplementation with ANT 10±7 mol/l (ANT + LA). For each patient,
one culture with four experimental treatments (basal, LA 100 ng/ml,
ANT 10±7 mol/l and LA + ANT) were assessed in quadruplicate.
The percentage of apoptotic cells was assessed by the acridine
orange±ethidium bromide technique in endometrial cultures, under
basal conditions and after exposure to the different agents (GnRH
agonist, GnRH antagonist or both).
Acridine orange is a vital dye that is excluded from viable cells. It is
speci®c for apoptotic forms of cell death and does not signi®cantly
label cells undergoing necrotic death caused by injury (Abrams et al.,
1993). After addition of the acridine orange (1 mg/l)±ethidium
bromide (250 mg/l) mix, the cells were viewed by a ¯uorescence
microscope and the apoptotic cells were counted manually as a
percentage of the total number of cells by two independent observers.
Each observer viewed 30 randomly selected ®elds in a blind manner.
There was no signi®cant difference in results between the two
observers (P = 0.63).
Quanti®cation of IL-1b and VEGF
Epithelial cells cultures were left undisturbed at 37°C for 2 days.
Subsequently, the cells were washed and incubated with basic medium
supplemented with 2.5% FBS for an additional 48 h under basal
conditions, after the addition of LA at 100 ng/ml, ANT at 10±7 mol/l
and ANT 10±7 mol/l + LA 100 ng/ml. The conditioned medium was
collected and assayed for IL-1b and VEGF using commercial enzyme-
linked immunoassay (ELISA) kits (Cytimmune Sciences Inc., MD,
USA). The sensitivity level for the IL-1b ELISA was 0.87 pg/ml and
for the VEGF ELISA was 18.6 pg/ml.
The intra-assay variability for IL-1b and VEGF was 67.9 and 8.9%
respectively, while the inter-assay variability was 611.4 and 11.1%
for IL-1b and VEGF respectively. All samples were assessed in
triplicate.
Statistics
Statistical comparisons were performed by Kruskal±Wallis non-
parametric ANOVA test, followed by Dunn¢s multiple comparison





Effects of GnRH agonist and antagonist on epithelial
endometrial cell apoptosis
Exposure to LA signi®cantly increased the level of apoptosis in
cultures from patients and controls. LA at 100 ng/ml showed an
effect on endometrial growth, enhancing apoptosis in endo-
metrial cell cultures from patients with endometriosis from
23.9 6 8.0 to 41.7 6 9.6% (expressed as a percentage of
apoptotic cells, mean 6 SD, P < 0.01) (Figure 1A), and from
18.2 6 6.3 to 42.5 6 14.7% in cultures from controls (P < 0.05)
(Figure 1B). In both experiments, this effect was prevented by
adding ANT at 10±7 mol/l (3 h prior to adding LA): in
endometriosis 31.0 6 4.9%, and in controls 27.3 6 8.1%
(versus basal, P > 0.05, NS) (Figure 1A and B). ANT by itself,
at 10±7 mol/l, had no visible effect on basal apoptosis (Table I).
Effects of GnRH agonist and antagonist on IL-1b release
by epithelial endometrial cell cultures
Exposure to LA signi®cantly decreased the levels of IL-1b,
from 223.0 6 56.0 to 83.6 6 16.3 pg/ml (P < 0.05), and from
201.5 6 58.6 to 96.1 6 54.8 pg/ml (P < 0.03), in conditioned
media from endometrial cell cultures in endometriosis patients
and controls respectively (Figure 2).
This effect was prevented by adding ANT at 10±7 mol/l (3 h
prior to LA): in endometriosis patients 124.0 6 32.3 pg/ml, and
in controls 177.6 6 64.1 pg/ml (versus basal, P > 0.05, NS)
(Table I).
Endometrial cell cultures from endometriosis patients and
controls treated with ANT at 10±7 mol/l by itself did not show
any signi®cant difference compared with the levels of IL-1b
found under basal conditions (Table I).
It is of interest that there was no difference in the release of
IL-1b between the endometrial cell cultures from endome-
triosis and control patients.
Effects of GnRH agonist and antagonist on VEGF release
by epithelial endometrial cell cultures
Exposure to LA signi®cantly decreased the levels of VEGF
from 283.6 6 83.9 to 134.5 6 37.3 pg/ml (P < 0.04), and from
250.9 6 60.8 to 96.0 6 11.0 pg/ml (P < 0.03), in conditioned
media from endometrial cell cultures in endometriosis patients
and controls respectively (Figure 3).
This effect was prevented by adding ANT at 10±7 mol/l (3 h
prior to LA): in endometriosis, 215.8 6 102.4 pg/ml, and in
controls 317.5 6 90.5 pg/ml (versus basal, P > 0.05, NS)
(Table I).
Endometrial cell cultures from endometriosis patients and
controls treated with ANT at 10±7 mol/l alone, did not show any
signi®cant difference in the levels of VEGF compared with
basal conditions.
Figure 1. Effects of LA and ANT on apoptosis in endometrial cell
cultures from subjects with (A) and without endometriosis (B).
Epithelial cell cultures from patients with endometriosis and control
subjects were analysed for apoptosis by the acridine orange±
ethidium bromide technique under basal conditions and stimulated
with LA 100 ng/ml or ANT at a concentration of 10±7 M, or a
combination of ANT and LA. Values are expressed as a percentage
of apoptotic cells. The cells were viewed by a ¯uorescence
microscope and apoptotic cells are expressed as a percentage of the
total (see text). *P < 0.01 versus basal; **P < 0.05 versus basal;
ANT 10±7 mol/l and ANT 10±7mol/l + LA 100 ng/ml versus basal,
P > 0.05, NS.
Table I. Apoptosis, IL-1b and VEGF release in epithelial endometrial cultures (EEC) from endometriosis patients and controls. Values are mean 6 SD.
EEC from endometriosis patients EEC from controls
ApC (%) IL-1b (pg/ml) VEGF (pg/ml) ApC (%) IL-1b (pg/ml) VEGF (pg/ml)
Basal 23.9 6 8.1+ 223.0 6 56.0* 283.6 6 83.9** 18.2 6 6.3* 201.5 6 58.6++ 250.9 6 60.8++
LA 41.7 6 9.7+ 83.6 6 16.3* 134.5 6 37.3** 42.5 6 14.7* 96.1 6 54.8++ 96.0 6 11.0++
ANT 28.4 6 10.8 175.6 6 56.2 248.8 6 76.9 23.4 6 9.1 116.6 6 17.4 302.5 6 160.2
LA + ANT 31.0 6 4.9 124.0 6 32.3 215.8 6 102.4 27.4 6 8.1 177.6 6 64.1 317.5 6 90.5
The percentage of apoptotic cells (ApC) was estimated by the acridine orange±ethidium bromide technique under basal conditions and stimulated with
leuprolide acetate (LA) 100 ng/ml or antide (ANT) at a concentration of 10±7 mol/l, or a combination of ANT and LA. The cells were viewed by a ¯uorescence
microscope and apoptotic cells are expressed as a percentage of the total.
The unstimulated (basal) and stimulated conditioned media from EEC were collected and assayed for IL-1b and VEGF using commercial ELISA kits.
+P < 0.01, ++P < 0.03, **P < 0.04 and *P < 0.05 basal versus LA.
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In addition, we found no differences in VEGF release
between endometrial cell cultures from endometriosis patients
and controls (Table I).
Discussion
Endometriotic implants are known to regress following the
induction of hypo-estrogenism. To date, the basis of most of
the therapeutic agents for endometriosis, including GnRH
agonists and GnRH antagonists, is to achieve regression of the
endometriotic implants through the induction of systemic
hypo-estrogenism (Rice, 2002). The local anti-proliferative
effects of GnRH agonists seems to be not only through
suppression of gonadal steroids, but also through a direct effect
on cell growth. There is convincing in-vitro evidence showing
that GnRH agonists can directly inhibit the proliferation of
endometrium as well as several types of cancer cells (Emons
et al., 1998; Meresman et al., 2003).
In this study, epithelial cell cultures of human endometrium
were used as a model to evaluate apoptosis, as well as IL-1b and
VEGF release, in response to the addition of a GnRH agonist, a
GnRH antagonist or both to the cultures. Although the cells
employed in this investigation were not derived from endome-
triotic implants, and therefore their in-vitro response may not be
identical, the rationale for the use of endometrial cells in short-
term culture as a model for endometriotic implants is scientif-
ically acceptable and has been documented in the literature
(Surrey and Halme, 1990; Meresman et al., 2003).
In our study, we found that LA increased the apoptotic rate
in eutopic endometrial cells from controls and endometriosis
patients. This ®nding is in agreement with the report by Andreu
et al. (1998), showing that incubation with a GnRH agonist
stimulated apoptosis in rat granulosa cells, as well as with a
recent study reporting that a GnRH agonist triggered apoptosis
in a single suspension of stromal and glandular epithelial
endometrial cells from patients with endometriosis (Imai et al.,
2000). These ®ndings, as well as the data contained in the
present study, seems to con®rm that GnRH agonists may be
effective in reducing the growth of endometrial cells not only
through an indirect effect (via causing hypoestrogenism), but
also through a direct effect on the endometrial tissue.
VEGF is an important angiogenic factor and IL-1b is an
important pleiotrophic factor that appear to be involved in the
establishment and progression of endometriosis (Lebovic et al.,
2000). The human endometrium and endometriotic tissue were
found to express signi®cant levels of VEGF and IL-1b (Donnez
et al., 1998; Bergqvist et al., 2001). In addition, their
concentrations were found to be elevated in peritoneal ¯uid
from patients with endometriosis (Mori et al, 1992; McLaren
et al., 1996) and it was suggested that IL-1b could induce
VEGF expression in endometriotic cells (Lebovic et al., 2000).
In the present study, we showed for the ®rst time that VEGF
and IL-1b content in the conditioned media from endometrial
cell cultures exposed to a GnRH agonist were signi®cantly
lower than the concentrations encountered under basal condi-
tions in the same cultures. Our results are in agreement with
those of Kupker et al. (1998) suggesting that after GnRH
agonist therapy, endometriosis patients showed a signi®cant
drop in the mean concentrations of VEGF in the peritoneal
¯uid. VEGF expression was found to be elevated in the
endometrium from patients with endometriosis and in the
endometriotic tissue itself (Donnez et al., 1998; McLaren,
2000). We propose that GnRH agonist therapy seems to
regulate the angiogenic activity of the endometriotic lesions by
modulating the secretion of angiogenic factors.
The same was true for IL-1b; Taketani et al. (1992) found
that the levels of this cytokine was signi®cantly higher in the
peritoneal ¯uid from women with active endometriosis,
compared with patients without the disease, but that the levels
were extremely low in women with endometriosis who had
undergone medical treatment with either danazol or buserelin.
Based on these data, and on our own results, the possibility
remains that GnRH agonists modulate the production of
speci®c cytokines, and in turn regulate the growth of the
endometriotic tissue.
In our study, the GnRH antagonist ANT by itself did not
produce any signi®cant effects on epithelial endometrial cells
in culture, but it was able to prevent the enhanced effect of the
Figure 3. Effects of LA on VEGF release by epithelial endometrial
cell cultures. Epithelial cell cultures from patients with endometriosis
(EDT) and control subjects were incubated under basal conditions or
with the addition of LA at 100 ng/ml; the conditioned media were
collected and assayed for VEGF using commercial ELISA kits.
*P < 0.04 versus basal; **P < 0.03 versus basal.
Figure 2. Effects of LA on IL-1b release by epithelial endometrial
cell cultures. Epithelial cell cultures from patients with endometriosis
(EDT) and control subjects were incubated under basal conditions or
with the addition of LA at 100 ng/ml; the conditioned media were
collected and assayed for IL-1b using commercial ELISA kits.
*P < 0.05 versus basal; **P < 0.03 versus basal.
G.F.Meresman et al.
1770
GnRH agonist on programmed cell death, and reversed the
inhibition by LA of VEGF and IL-1b release. These ®ndings
combined strongly suggest that the direct effects of GnRH
agonists on endometrial cells in vitro are probably mediated by
homologous GnRH receptors.
We did not ®nd signi®cant differences in the rate of
apoptosis or in VEGF and IL-1b release between endometrial
cell cultures from endometriosis patients and controls; this
®nding of a similar degree of apoptosis in these two different
groups of patients is in contrast to the results observed in whole
endometrial sections in our previous study (Meresman et al.,
2000). We could speculate that after 4 days in culture of the
glandular fraction, the epithelial endometrial cells altered their
initial conditions, and therefore we could not detect mainten-
ance of their apoptotic characteristics in comparison with when
the entire tissue was used.
In conclusion, GnRH agonists appear to have a direct local
effect on endometrial cells in culture; this effect is manifested
by the enhancement in the percentage of apoptotic cells as well
as by the signi®cant inhibition observed in the release of pro-
mitogenic cytokines such as IL-1b and VEGF. Furthermore,
we were unable to observe a signi®cant direct effect of a GnRH
antagonist on any of the parameters studied, on the same tissue
cultures, although it was able to reverse the effects caused by
the GnRH agonist.
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